An observational study in Venous Thromboembolism (VTE), sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-28.
Sponsored by Bristol-Myers Squibb · Observational
A study involving real-world database analysis to evaluate the hospital healthcare utilization and costs, and all-cause, major bleeding-, clinically relevant bleeding-, any bleeding-, and venous thromboembolism (VTE)-related hospital readmissions among hospitalized VTE patients treated with apixaban or warfarin, with or without low molecular weight heparin (LMWH)
818 studies on the registry are indexed under Thromboembolism; 98 are open to participants now.
This study's enrollment of 28,000 is above the median of 500 across 344 observational studies indexed under Thromboembolism.
Browse Thromboembolism studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will include patients with a hospital or ED discharge International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or ICD-10 code indicating a primary diagnosis of VTE identified from the Premier Hospital database between 01-Aug-2014 and 31-May-2016. Patients who received apixaban or warfarin with or without LMWH during any time of the hospitalization (from admission to discharge) will be identified. Patients receiving both apixaban and warfarin, or any other direct oral anticoagulant (DOAC), including rivaroxaban, dabigatran, and edoxaban, during the index hospitalizations will be excluded from the study population. Patients will be required to have no evidence of atrial fibrillation (AF) or atrial flutter (AFL) during the index hospitalizations or the baseline periods.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria could apply
With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
Hospital Length of stay (LOS)
Time frame: During the index hospitalization (Up to 30 days)
Hospital cost
Time frame: During the index hospitalization (Up to 30 days)
Proportion of patients with major bleeding (MB)-related hospital readmissions
Time frame: During 1 month after the index hospitalization
Proportion of patients with clinically relevant bleeding (CRB)-related hospital readmissions
Time frame: During 1 month after the index hospitalization
Proportion of patients with any bleeding-related hospital readmissions
Time frame: During 1 month after the index hospitalization
Proportion of patients with VTE-related hospital readmissions
Time frame: During 1 month after the index hospitalization
Proportion of patients with combined VTE- or MB-related hospital readmissions
Time frame: During 1 month after the index hospitalization
Proportion of patients with all-cause hospital readmissions
Time frame: During 1 month after the index hospitalization
Hospital Length of stay (LOS) for major bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital costs of readmissions for major bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital charges of readmissions for major bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization]
Mean number of hospital readmissions for major bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital LOS for clinically relevant bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital costs of readmissions for clinically relevant bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital charges of readmissions for clinically relevant bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Mean number of hospital readmissions for clinically relevant bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital LOS for any bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital costs of readmissions for any bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital charges of readmissions for any bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Mean number of hospital readmissions for any bleeding-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital LOS for VTE-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital costs of readmissions for VTE-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital charges of readmissions for VTE-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Mean number of hospital readmissions for VTE-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital LOS for combined VTE- or MB-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital costs of readmissions for combined VTE- or MB-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital charges of readmissions for combined VTE- or MB-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Mean number of hospital readmissions for combined VTE- or MB-related hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital LOS for all-cause hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital costs of readmissions for all-cause hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Hospital charges of readmissions for all-cause hospital readmissions
Time frame: During 1 month following the VTE hospitalization
Mean number of hospital readmissions for all-cause hospital readmissions
Time frame: During 1 month following the VTE hospitalization
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb